Therefore, approval of the applications listed in table 1, and all amendments and supplements thereto, is hereby withdrawn as of November 24, 2017. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in table 1 that are in inventory on the date that this notice becomes effective (see the DATES section) may continue to be dispensed until the inventories have reached their expiration dates or been depleted or the drug products have been removed from the market.

Dated: October 18, 2017.

Leslie Kux,
Associate Commissioner for Policy.

[FR Doc. 2017–23046 Filed 10–23–17; 8:45 am]
BILLING CODE 4164–01–P

TABLE 1—Continued

<table>
<thead>
<tr>
<th>Application No.</th>
<th>Drug</th>
<th>Applicant</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA 085720</td>
<td>Meprobamate Tablets USP, 200 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 085721</td>
<td>Meprobamate Tablets USP, 400 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 085778</td>
<td>Hydroxyzine HCI Injection USP, 25 mg/mL</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 086096</td>
<td>Chlorpheniramine Maleate Injection USP, 10 mg/mL</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 086189</td>
<td>Ergoloid Mesylates Sublingual Tablets USP, 0.5 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 086598</td>
<td>Nandrolone Decanoate Injection USP, 100 mg/mL</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 086795</td>
<td>Chlorothiazide Tablets USP, 250 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 087183</td>
<td>Ergoloid Mesylates Sublingual Tablets USP, 1 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 087296</td>
<td>Chlorthalidone Tablets USP, 25 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 087521</td>
<td>Chlorthalidone Tablets USP, 50 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 087772</td>
<td>Prednisone Tablets USP, 50 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 087979</td>
<td>Chloroquine Phosphate Tablets USP, EQ 150 mg base</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 088030</td>
<td>Chloroquine Phosphate Tablets USP, EQ 300 mg base</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 089042</td>
<td>Procainamide HCI Extended-Release Tablets USP, 750 mg</td>
<td>Do.</td>
</tr>
</tbody>
</table>

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44).

Date: November 17, 2017.

Time: 1:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).

Contact Person: Vasundhara Varthakavi, Ph.D., DVM, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room 3E70, National Institutes of Health, NIAID, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892–9823, (240) 669–5020, varthakavi@nih.gov. (Catalog of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: October 18, 2017.

Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2017–23046 Filed 10–23–17; 8:45 am]
BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; International Research Ethics Training.

Date: November 16, 2017.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892.

Contact Person: Karin F. Helmers, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3148, MSC 7770, Bethesda, MD 20892, (301) 254–9975, helmersk@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR16–121 Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01).

Date: November 16, 2017.

Time: 12:00 p.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Raul Rojas, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6185, Bethesda, MD 20892, (301) 496–6319, rojasr@mail.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Macromolecular Structure and Function.

Date: November 20, 2017.

Time: 1:00 p.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: C-L Albert Wang, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6185, Bethesda, MD 20892, (301) 496–6319, rojasr@mail.nih.gov.